Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.51 |
| ▸ | NMT2 | O60551 | 3/20 | 0.44 |
| ▸ | NMT1 | P30419 | 3/20 | 0.44 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.44 |
| ▸ | NPY4R | P50391 | 9/20 | 0.42 |
| ▸ | NPY1R | P25929 | 6/20 | 0.42 |
| ▸ | NPY2R | P49146 | 6/20 | 0.42 |
| ▸ | NPY5R | Q15761 | 6/20 | 0.42 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.41 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.41 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.41 |
| ▸ | TLR2 | O60603 | 1/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5598713 | 1.00 | SLC15A2 (0.51) | SLC15A2NMT2NMT1FOLH1NPY4R | |
| SCHEMBL30372694 | 1.00 | SLC15A2 (0.51) | SLC15A2NMT2NMT1FOLH1NPY4R | |
| SCHEMBL31106970 | 1.00 | SLC15A2 (0.51) | SLC15A2NMT2NMT1FOLH1NPY4R | |
| SCHEMBL5598706 | 1.00 | SLC15A2 (0.51) | SLC15A2NMT2NMT1FOLH1NPY4R | |
| SCHEMBL31717990 | 1.00 | SLC15A2 (0.51) | SLC15A2NMT2NMT1FOLH1NPY4R | |
| SCHEMBL30713830 | 1.00 | SLC15A2 (0.51) | SLC15A2NMT2NMT1FOLH1NPY4R | |
| SCHEMBL30373028 | 1.00 | SLC15A2 (0.51) | SLC15A2NMT2NMT1FOLH1NPY4R | |
| SCHEMBL2241862 | 0.99 | SLC15A2 (0.50) | SLC15A2NMT2NMT1FOLH1NPY4R | |
| SCHEMBL4589283 | 0.99 | SLC15A2 (0.50) | SLC15A2NMT2NMT1FOLH1NPY4R | |
| SCHEMBL31472996 | 0.99 | SLC15A2 (0.50) | SLC15A2NMT2NMT1FOLH1NPY4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4554959-A2 | COMPOSITIONS INCLUDING MULTI-AGONIST PEPTIDES AND METHODS OF MANUFACTURE AND USE | Pep2Tango Therapeutics Inc. (US) | 2025-05-21 | — | — | EP | disclosed |
| CN-119529025-A | Milk protein peptide with zinc chelating activity and application thereof in preparation of zinc supplement | 华南农业大学 | 2025-02-28 | — | — | CN | disclosed |
| EP-4370537-A1 | COMPOSITIONS INCLUDING MULTI-AGONIST PEPTIDES AND METHODS OF MANUFACTURE AND USE | Pep2Tango Therapeutics Inc. (US) | 2024-05-22 | — | — | EP | disclosed |
| US-20240059753-A1 | COMPOSITIONS INCLUDING MULTI-AGONIST PEPTIDES AND METHODS OF MANUFACTURE AND USE | PEP2TANGO THERAPEUTICS INC. | 2024-02-22 | — | — | US | disclosed |
| WO-2024015922-A2 | COMPOSITIONS INCLUDING MULTI-AGONIST PEPTIDES AND METHODS OF MANUFACTURE AND USE | PEP2TANGO THERAPEUTICS INC. (US) | 2024-01-18 | — | — | WO | disclosed |
| WO-2023245240-A1 | PROMOTION OF SYNCHRONOUS SEXUAL MATURATION AND SPAWNING IN AQUATIC ANIMALS | Provectus Algae Pty Ltd (AU) | 2023-12-28 | — | — | WO | disclosed |
| US-20230203100-A1 | COMPOSITIONS INCLUDING MULTI-AGONIST PEPTIDES AND METHODS OF MANUFACTURE AND USE | PEP2TANGO THERAPEUTICS INC. | 2023-06-29 | — | — | US | disclosed |
| WO-2023288313-A1 | COMPOSITIONS INCLUDING MULTI-AGONIST PEPTIDES AND METHODS OF MANUFACTURE AND USE | PEP2TANGO THERAPEUTICS INC. (US) | 2023-01-19 | — | — | WO | disclosed |
| US-11300519-B2 | Reagents and methods for detecting infectious diseases | IONICA SCIENCES (US) | 2022-04-12 | — | — | US | disclosed |
| CN-112094316-B | High-zinc-chelating-activity zinc chelating peptide with Ser and Cys arranged at two ends and application thereof | 安徽省农业科学院农产品加工研究所 | 2022-04-08 | — | — | CN | disclosed |
| CN-111909238-B | High-zinc-chelation-activity zinc chelating peptide containing Ser-Cys and application thereof | 安徽省农业科学院农产品加工研究所 | 2022-04-08 | — | — | CN | disclosed |
| CN-111925411-B | Cys-Ser-containing high-zinc-chelating-activity zinc chelating peptide and application thereof | 安徽省农业科学院农产品加工研究所 | 2022-04-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203100-A1 | COMPOSITIONS INCLUDING MULTI-AGONIST PEPTIDES AND METHODS OF MANUFACTURE AND USE | IAPP, GPR119, GIPR | SLC15A2 1922/4885NMT2 1183/4885NMT1 1541/4885 |
| US-20240059753-A1 | COMPOSITIONS INCLUDING MULTI-AGONIST PEPTIDES AND METHODS OF MANUFACTURE AND USE | IAPP, GPR119, GIPR | SLC15A2 1922/4885NMT2 1183/4885NMT1 1541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.